** Jefferies says Healius HLS.AX sees strong second half growth for its pathology business
** Analysts at Jefferies forecast for HLS' pathology business an EBIT margin of 1.1% in 1HFY25 and 4.6% 2HFY25
** The Aussie healthcare firm said on Friday it sees 1H25 EBIT for its pathology business broadly in line with 1H24, while anticipating an increase in pathology earnings in 2HFY25
** Company's 1HFY24 EBIT was A$6 million ($3.88 million) while Jefferies estimate was A$7 million
** Brokerage says HLS's elevated cost base continues to be an issue
** Brokerage cuts price target for co to A$1.45 from A$1.75; retains "hold" rating
** HLS down 18.4% so far this year as of last close, underperforming against a 3.7% gain on the ASX Health Care index .AXHJ
($1 = 1.5482 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.